Center for Drug Research and Evaluation discusses why the drug was withdrawn, how it came to be approved and what to do if you're taking it.

FDA reports on Glaxo's decision to withdraw irritable bowel medication after receiving reports of ischemic colitis in patients taking the drug.

September 1, 1999 press release on the FDA designation of Glaxo Wellcome's investigational 5-HT3 antagonist Lotronex for priority review.

Official Lotronex site from GlaxoWellcome features an extensive profile of the drug. Includes news and information for health care professionals.